On September 23, 2026, Armata Pharmaceuticals, Inc. (NYSE American: ARMP) announced that it has secured an additional $3.7 million in non-dilutive funding from the U.S. Department of War (DoW). This financial commitment is designated to support activities associated with the Phase 3 development program for AP-SA02, the company’s intravenously administered multi-phage product candidate.
The new funding is the first specifically allocated for Phase 3 execution under a previously announced Department of War award. It was received through the Medical Technology Enterprise Consortium (MTEC) and managed by the Naval Medical Research Command (NMRC) – Naval Advanced Medical Development (NAMD), with support from the Defense Health Agency and the Joint Warfighter Medical Research Program.
According to the filing, this $3.7 million brings the cumulative non-dilutive DoW funding for the AP-SA02 program to approximately $32.4 million. The company’s lead clinical candidate, AP-SA02, is being developed as an adjunctive treatment for complicated Staphylococcus aureus bacteremia (SAB) caused by methicillin-sensitive (MSSA) or methicillin-resistant (MRSA) strains.
AP-SA02 has received Qualified Infectious Disease Product (QIDP) designation, Fast Track designation, and Breakthrough Therapy designation from the FDA. The company plans to advance AP-SA02 into a Phase 3 superiority study in complicated SAB, with an anticipated initiation in the second half of 2026.
